Research conducted by a local hospital has found that hepatitis B patients with a simple fatty liver have a lower mortality ...

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

On , Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Course- based Undergraduate Research Experiences (CUREs) by incorporating nine essential elements of research, relevance, scientific background, hypothesis development, research proposal, all aspects ...

Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths increased from 1.1 million in 2019 to 1.3 million in 2022, rates now similar ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

The recovery can extend from anywhere between six to 12 months and occasionally up to three years. Currently, there is no certain cure for Guillain-Barré Syndrome. The paralysis not only affects the ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

Please provide your email address to receive an email when new articles are posted on . The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran ...